For Immediate Release:

Contact: Allen & Caron Inc   CLOSURE Medical Corp
  Jay McKeage (investors) Len Hall (media) Benny Ward, CFO
  (212) 691-8087 (949) 474-4300 (919) 876-7800
  jay@allencaron.com len@allencaron.com  

CLOSURE MEDICAL CORPORATION TO PRESENT AT THE PACIFIC GROWTH EQUITIES LIFE SCIENCES GROWTH CONFERENCE

RALEIGH, NC (June 1, 2004) … CLOSURE Medical Corporation (Nasdaq:CLSR), a global leader in biomaterial-based medical devices, is scheduled to present at the Pacific Growth Equities Life Sciences Growth Conference at the Mark Hopkins Inter-Continental Hotel in San Francisco on Thursday, June 10, 2004.

Daniel A. Pelak, President & CEO, will deliver the Company’s presentation beginning at approximately 11:00 a.m. EDT (8:00 a.m. PDT). A live audio webcast of the presentation will be available via a link provided under the Investor section of CLOSURE Medical’s website at www.closuremed.com. An archive of the presentation will be available for 14 days.


About CLOSURE Medical Corporation
CLOSURE Medical Corporation is a global leader in the development and manufacture of innovative biomaterial-based medical devices that fulfill the needs of healthcare practitioners, patients and consumers.

For additional information on CLOSURE Medical visit its website at www.closuremed.com or visit the “Clients” section of the Allen & Caron website at www.allencaron.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company’s products; the progress of its research and development programs for future products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; the satisfactory conclusion of negotiations with, and dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2003, filed with the Securities and Exchange Commission. Although the Company believes that the expectations in the forward-looking statements are reasonable, the Company cannot guarantee such results. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.